Suven Life Sciences Ltd (Suven) announces that the European Patent Office (EPO) has issued three new patents: EP1537113, EP1704154 and EP1856132 corresponding to three New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these Patents are valid until 2022,23 and 24 respectively.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s, ADHD, Parkinson, Schizophrenia and Huntington’s diseases.

With these new patents, Suven has total of seven granted EPO patents on NCEs. All the seven EPO patents have been validated in the 37 member countries of Europe. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various stages of clinical development like at phase-I or phase-II.

"We are very pleased by the grant of these patents to Suven by EPO for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated US$ 20 billion market potential globally," said Venkat Jasti, CEO of Suven.